Study #2014-0193
A Phase 1b Trial of LY2606368 in Combination with Cisplatin or Cetuximab in Advanced and/or Metastatic Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Prexasertib, Cisplatin, G-CSF, Cetuximab, Pemetrexed, Fluorouracil, Leucovorin, LY3023414
Description
The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-499-8634
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.